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In Brief A chimeric antigen receptor system that can integrate signals from multiple antigens and fine-tune T cell activation in a cell-type-specific manner holds promise for enhancing the safety and specificity of CAR T cell therapies for cancer treatment.
INTRODUCTION
The transfer of chimeric antigen receptor (CAR)-expressing T cells to patients is a promising approach for cancer immunotherapy (Brentjens et al., 2011; Davila et al., 2014; Grupp et al., 2013; Maude et al., 2014a) . Despite these encouraging results, safety and efficacy continue to be major hurdles that hinder CAR T cell therapy development (Brentjens et al., 2013; Kochenderfer et al., 2012; Morgan et al., 2010; Scholler et al., 2012) . To improve overall effectiveness and safety of CAR T cell therapy, there is an urgent need for a better system that can finely tune T cell activation, enhance tumor specificity, and independently control different signaling pathways and cell types.
The CAR T cells used in clinical trials typically have a rigid design that is difficult to alter without re-engineering the T cells. Current CAR designs are composed of a fixed antigenspecific single-chain variable fragment (scFv) and intracellular signaling domains (CD3z and costimulatory domains). When the constant antigen-specific CAR binds to the target antigen, these invariable signaling domains are activated simultaneously at a predetermined level. Due to the fixed design that limited the controllability of CAR T cell activation level, managing CAR T cell-related toxicities have proven to be challenging (Brentjens et al., 2013; Brudno and Kochenderfer, 2016; Davila et al., 2014) .
In addition to constraining the controllability of CAR T cell activity, this fixed CAR design also restricts the antigen specificity and affinity. High-affinity scFvs are often used in the CAR design to ensure high antigen specificity. However, CARs made with high-affinity scFvs have limited capacity in discriminating antigen density, which has led to dangerous reactivity against healthy organs expressing a low level of antigens (Bonifant et al., 2016; Morgan et al., 2010) . Using a scFv with lower antigen affinity allowed better antigen density discrimination (Caruso et al., 2015; Liu et al., 2015) , but antigen specificity may be compromised. Thus, modulation of CAR components other than scFv affinity may be needed for improving CAR T cell specificity.
Recently, several studies have demonstrated the importance of regulating CD3z and the different costimulatory pathways independently to achieve optimal T cell response (Kloss et al., 2013; Lanitis et al., 2013; Zhao et al., 2015) . Also, the activation of different costimulatory domains (e.g., CD28 or 4-1BB) is known to have different T cell functions and phenotypes (e.g., T cell differentiation, memory T cell formation) (Kawalekar et al., 2016; Skapenko et al., 2001; Zhu et al., 2007) , demonstrating the value of CAR design that allows independent control of different signaling domains.
The composition of the T cell subsets, such as the ratio of CD4+ and CD8+ T cells, has also been shown to be an important parameter for enhancing the antitumor response of CAR T cells (Turtle et al., 2016) . Given the fact that our immune system is composed of many different T cell subtypes with distinct effector functions (Golubovskaya and Wu, 2016; Vignali et al., 2008; Vivier et al., 2008) , regulating the activity of T cell subtypes independently may be an attractive strategy for optimizing the efficacy of CAR T cell therapy (Sadelain et al., 2017) . However, current fixed CAR design limits independent and inducible activation of different signaling domains or different T cell subsets to achieve user-defined diverse T cell response.
New receptor designs have been developed to address some of the deficiencies (e.g., controllability, flexibility, specificity) in (A) Comparison between the conventional CAR and SUPRA CAR design. A SUPRA CAR system is composed of a zipCAR and zipFv. A zipCAR has a leucine zipper as the extracellular portion of the CAR and zipFv has a scFv fused to a cognate leucine zipper that can bind to the leucine zipper on the zipCAR. (B) A SUPRA CAR system targeting multiple tumor antigens using different zipFvs. K562 cells expressing Her2, Mesothelin, or Axl were co-cultured in vitro with RR zipCAR expressing CD8+ human primary T cells (n = 3, mean ± SD). (C) Variables explored for characterization of the SUPRA CAR system: (1) the affinity between leucine zipper pairs, (2) the affinity between tumor antigen and scFv, (3) the concentration of zipFv, and (4) the expression level of zipCAR. (D) Effect of concentration of three zipFvs with leucine zippers (SYN 3, SYN5, and EE) that have different affinities to RR zipCAR on the IFN-g production by primary CD4+ T cells (n = 3, mean ± SD). (E) Effect of zipper affinity, scFv tumor affinity, and zipCAR expression level on the IFN-g production by primary CD4+ T cells expressing RR zipCAR (n = 3, mean). See also Figures S1 and S2. current CAR T cell therapies. For instance, drug-inducible ON and kill switches have been developed to regulate CAR activity (Di Stasi et al., 2011; Wu et al., 2015) . Also, to afford greater flexibility in antigen recognition, CARs have been split such that the antigen recognition motif is dissociated from the signaling motif of the CAR. This split CAR configuration uses a universal receptor as the common basis for all interactions, allowing a large panel of antigens to be targeted without re-engineering the immune cells (Cartellieri et al., 2016; Rodgers et al., 2016; Tamada et al., 2012; Urbanska et al., 2012) . In addition, to increase tumor specificity, CARs were developed that allow combinatorial antigen sensing (Kloss et al., 2013; Lanitis et al., 2013; Roybal et al., 2016) or target two tumor-specific antigens that can reduce tumor antigen escape rate (Grada et al., 2013; Zah et al., 2016) . All of these features are arguably vital to ensure a safe and effective CAR T therapy. However, none of these advanced CARs has incorporated all of these features into one system. Additionally, the signaling pathways and cell types that can be activated are also fixed, thus limiting the diverse immune responses that can be achieved.
To enhance the specificity, safety, and programmability of CARs, we develop a split, universal, and programmable (SUPRA) CAR system composed of a universal receptor expressed on T cells and a tumor-targeting scFv adaptor molecule ( Figure 1A ).
The activity of SUPRA CARs can be finely regulated via multiple mechanisms to limit overactivation. SUPRA CARs can also logically respond to multiple antigens for improving tumor specificity. We show that the SUPRA CAR system is effective against two different tumor models, demonstrating the broad clinical potential of this system. In addition, we show that SUPRA components can be humanized to reduce potential immunogenicity. Furthermore, we use orthogonal SUPRA CARs to inducibly regulate multiple signaling pathways or different human T cell subtypes to increase the range of the immune responses that can be achieved. Together, the SUPRA CAR system is a feature-rich system with inducible and logical control capabilities that can improve the safety and efficacy of current cellular cancer immunotherapy.
RESULTS

Design and Characterization of the SUPRA CAR System
The SUPRA CAR is a two-component receptor system composed of a universal receptor (zipCAR) expressed on T cells and a tumor-targeting scFv adaptor (zipFv) ( Figure 1A ). The zipCAR universal receptor is generated from the fusion of intracellular signaling domains and a leucine zipper as the extracellular domain. The zipFv adaptor molecule is generated from the fusion of a cognate leucine zipper and a scFv. The scFv of the zipFv binds to the tumor antigen, and the leucine zipper binds and activates the zipCAR on the T cells ( Figures S1A and S2 ). Unlike the conventional fixed CAR design, the SUPRA CAR modular design allows targeting of multiple antigens without further genetic manipulations of a patient's immune cells (Figure 1B, left) . To test the ability of the SUPRA CAR system targeting multiple antigens with the same batch of T cells expressing the zipCAR, we first engineered human primary CD8+ T cells to express an RR zipCAR (RR leucine zipper with CD28, 4-1BB co-stimulatory and a CD3z signaling domain; Figure S1A ). Next, we designed three different zipFvs to target three common tumor antigens (a-Her2, a-Axl, and a-Mesothelin; Figure S1A ) by fusing the corresponding scFvs to an EE leucine zipper, which binds to the RR zipCAR on T cells. The engineered CD8+ T cells were co-cultured in vitro with K562 myelogenous leukemia cells that express Her2, Axl, or Mesothelin tumor antigens. The CD8+ zipCAR T cells killed the corresponding tumor cells when the matching zipFvs were added ( Figure 1B, right) .
A unique feature of the split CAR design is that it has multiple tunable variables, such as (1) the affinity between leucine zipper pairs, (2) the affinity between tumor antigen and scFv, (3) the concentration of zipFv, and (4) the expression level of zipCAR, that can be used to modulate the T cell response ( Figure 1C ). We first characterized the effect of zipFv concentration and zipper affinity on T cell activation. We generated three zipFvs with the same a-Her2 scFv but fused to leucine zippers (SYN5, SYN 3, and EE) that have different affinity to the RR zipCAR (Reinke et al., 2010; Thompson et al., 2012) . The amount of zipFv required to activate T cells to half-maximal interferon (IFN)-g secretion and cytotoxicity inversely correlated with the affinity of leucine zipper pairs where a-Her2-EE zipFv showed the lowest EC 50 and a-Her2-SYN5 zipFv showed the highest EC 50 value ( Figures 1D and S1C ). Also, the maximum level of IFN-g secretion or killing efficiency correlated with the affinity of leucine zipper pairs.
We next investigated the effect of scFv-tumor antigen affinity, leucine zipper affinity, and zipCAR expression levels on the IFN-g secretion and cancer-killing efficiency by the SUPRA CAR T cells ( Figures 1E and S1D) . We created 12 different zipFvs (three different leucine zippers with different affinity and four scFvs against Her2 [G98, C65, ML39, and H3B1] with K d ranging from 3.2 3 10 À7 to 1.2 3 10 À10 M) (Chmielewski et al., 2004) . We also generated two batches of T cells with high or low RR zipCAR expression level using fluorescence-activated cell sorting (FACS) ( Figure S1B ). Cells expressing higher levels of zipCAR exhibited greater cytokine secretion when activated ( Figure 1E ). The affinity of scFv to Her2 correlated weakly with cytokine secretion or target cell lysis (Chmielewski et al., 2004) . The affinity between leucine zippers, however, correlated well with cellular activation regarding cancer cell killing efficiency and cytokine secretion. As high-affinity scFv CARs often over-activate and show severe toxicities in clinical trials (Bonifant et al., 2016; Brudno and Kochenderfer, 2016) , the SUPRA platform can mitigate these toxicities by controlling other factors (e.g., zipFv concentration, affinity between leucine zipper pairs) to regulate T cell activation level. Together, these results demonstrate the tunable and modular nature of the SUPRA CAR design.
Competitive zipFvs for Tuning SUPRA CAR Activity As many patients treated with CAR T cell therapy face cytokine release syndrome, which can be life threatening (Maude et al., 2014b; Morgan et al., 2010) , it is important to prevent CAR T cell activity when necessary. Thus, we explored the possibility of inhibiting the SUPRA CAR T cell activation through the addition of a competitive zipFv that can bind to the other zipFv, thus preventing zipCAR from being activated (Figure 2A , left).
To test this approach, we screened several competitive zipFvs with different affinities for the EE zipFv (strong, medium, and weak) (Figures S3B and S3C) . Human CD8+ T cells were transduced with RR zipCAR and co-cultured with Her2+ K562 cells. Then, EE zipFv (22.5 nM, red) was subsequently added to activate the T cells. Without the competitive zipFv, the EE zipFv alone could activate T cells to destroy Her2+ cancer cells (Figure 2A, right) . However, when the competitive zipFv (SYN4, SYN 47, or SYN 13) was also introduced (90 nM, green), it bound to the EE zipFv and prevented the EE zipFv from activating the zipCAR T cells. By utilizing this competitive approach, we were able to inhibit primary CD8+ T cell activation in vitro with the strong competitive zipFv (SYN4). Furthermore, we were able to tune the activation levels with weaker binding zippers (SYN 47 and SYN 13). To understand inhibition dynamics, we varied the amount of competitive zipFv and timing of its addition. Increasing the amount of competitive zipFv or delaying competitive zipFv addition did not affect inhibition strength greatly ( Figure S3D ).
Logical Operation with the SUPRA CAR System
Antigen escape is a major challenge for targeted cancer therapies (Scott et al., 2012) , including adoptive T cell therapies Perna and Sadelain, 2016) . As such, bispecific receptors that can be triggered by CD19 and Her2 or CD19
and CD20, respectively, have been developed to combat antigen escape (Grada et al., 2013; Zah et al., 2016) . Also, CD22 and CD123 CARs have been recently developed to increase tumor specificity (Haso et al., 2013; Ruella et al., 2016) . However, as illustrated in a recent clinical trial with CD22 CAR T cells for patients relapsed from CD19 CAR T therapy, tumors can still evade detection by the engineered T cells by losing or downregulating both antigens (Fry et al., 2018) . In such cases, T cells would need to be re-engineered to target another antigen. Using the SUPRA CAR platform, however, different antigens can be easily targeted without further genetic manipulation. To test if SUPRA CAR could be used to target either one of the two antigens on the cell surface, we co-cultured Her2/Axl+ K562 cancer cells with RR zipCAR expressing CD8+ T cells. Then, different zipFv combinations were added to the cell mixture (a-Axl zipFv, a-Her2 See also Figure S3 .
zipFv, or both) ( Figure 2B ). As expected, the addition of zipFv targeting either Her2, Axl, or both led to high killing efficiency, illustrating the potential of programming the SUPRA CAR system to combat antigen escape. Another limitation of targeted tumor therapy is the difficulty in identifying a single tumor-specific antigen, which affects both tumor specificity and toxicity. Receptor systems that can perform combinatorial antigen detection have been developed to enhance the specificity of CAR T cell therapy (Kloss et al., 2013; Roybal et al., 2016) . However, these receptor systems have a fixed antigen specificity design. Here, we investigated if the SUPRA CAR system can also be used to increase tumor specificity through combinatorial antigen sensing ( Figure 2C ). In particular, we used the SUPRA CAR system to target cells that express Her2 only and spare cells that express both Her2 and Axl, where Axl served as a ''safety marker.'' To achieve our design, we developed an a-Axl-SYN2 zipFv (green) that binds to a-Her2-EE zipFv (red) through a complementary zipper on each zipFv; this prevents the a-Her2-EE zipFv from binding to the zipCAR, thus protecting the Her2+/Axl+ cells. In contrast, since a-Axl-SYN2 zipFv cannot bind to Her2-only cells, the a-Her2-EE zipFv will not be blocked from activating the zipCAR.
To demonstrate such Her2, but not Axl, logical operation, we first co-cultured RR zipCAR expressing CD8+ T cells with Her2+/Axl+ cells and zipFvs ( Figure 2C , left). As expected, the addition of the a-Her2-EE zipFv alone achieved high tumorkilling efficiency. However, when the a-Her2-EE zipFv was added after the a-Axl-SYN2 zipFv, the two zipFvs bound to A) (Left) The tumor burden was quantified as the total flux (photons/s) from the luciferase activity of each mouse using IVIS imaging. Compared to RR zipCAR or tumor-only control groups, the RR zipCAR + EE zipFv group showed significantly reduced tumor burden, comparable to conventional Her2 CAR (red arrow indicates injection of engineered CD8+ T cells and highlighted region indicates injection of zipFv [every 2 days at 5 mg/kg for 2 weeks]). (Right) Representative IVIS images of groups treated with (1) no T cells, (2) conventional Her2 CAR, (3) RR zipCAR, and (4) RR zipCAR with EE zipFv at day 41 (n = 4, mean ± SEM). (B) Representative IVIS images of groups treated with (1) no T cells, (2) RR zipCAR, (3) a-Her2 RR zipFv with RR zipCAR (non-binding), and (4) a-Her2 EE zipFv with RR zipCAR (complete SUPRA) (day 57, Figure S4B ). (C) Tumor burden as total flux (photons per sec) of each mouse shown in Figure 3B (n = 4, mean ± SEM). (D) In vivo IFN-g cytokine level after 24 hr of initial CD8+ T cells and zipFv injection (n = 4, mean ± SD). (E) (Left) Jurkat tumor cells were injected intravenously on day 0 to immune-compromised NSG mice. At day 3, primary human CD8+ T cells expressing RR zipCAR were injected once (red arrow) with a-Her2-EE zipFv, which was dosed every day for 6 days at 3 mg/kg (highlighted). The tumor burden was quantified as (legend continued on next page) each other and prevented the activation of the zipCAR, which led to a significant reduction in cytotoxicity ( Figure 2C, right) . As a control, we designed an a-Axl-SYN13 zipFv that did not bind strongly to the a-Her2-EE zipFv and showed no inhibition of T cell activity ( Figure S3E ). When the same SUPRA CAR system was challenged equally with cells expressing only Her2, the presence of a-Her2-EE zipFv alone again showed a high cytotoxicity rate ( Figure 2C, right) . Moreover, the addition of a-Axl zipFvs did not affect the killing efficiency. For both dual-and single-antigen target cells, a-Axl-SYN2 zipFv that binds strongly to a-Her2-EE zipFv or a-Axl-SYN13 zipFv that does not bind strongly to a-Her2-EE zipFv was first added to the cell mixture. After unbound a-Axl zipFvs were washed away, a-Her2-EE zipFv was added to stimulate CD8+ T cell activity (refer to STAR Methods for further detail). As expected, RR zipCAR engineered CD8+ T cells showed high activity toward Her2+ cancer cells, regardless of zipFv combinations, thus demonstrating the potential of the SUPRA CAR system to increase tumor specificity and reduce the toxicity of CAR T cell therapy.
Tumor Clearance in a Xenograft Tumor Model
After characterizing the SUPRA CAR system in vitro, we next tested whether SUPRA CARs can be used to reduce the tumor burden in a mouse xenograft model. For this experiment, we injected SK-BR-3 breast cancer cells (Her2 positive) intraperitoneally into immunocompromised NOD.Cg-Prkdc scid Il2rg tm1Wjl / SzJ (NSG) mice. After 2 weeks to allow for tumor establishment, we injected primary CD8+ human T cells expressing RR zipCAR or conventional Her2 CAR into the mice. a-Her2-EE zipFv was subsequently injected every 2 days at 5 mg/kg for 2 weeks. Tumor growth was monitored by in vivo imaging (IVIS) of the luciferase signal from SK-BR-3 cancer cells in each mouse over the course of 41 days. RR zipCAR with a-Her2-EE zipFv showed robust tumor burden clearance, comparable to the conventional Her2 CAR. However, T cells expressing RR zipCAR alone without zipFvs were not able to reduce tumor burden ( Figure 3A) .
To verify that the decrease in tumor burden was due to binding between zipCAR and zipFv, we also tested an a-Her2-RR zipFv, which does not bind to the RR zipCAR ( Figures 3B and S4A ). We set up a similar tumor model with SK-BR-3 breast cancer cells and injected RR zipCAR expressing CD8+ T cells at day 38 (Figures S4A and S4B) . Both zipFvs (a-Her2-RR or a-Her2-EE) were dosed every 2 days for 2 weeks at 8 mg/kg. Representative IVIS images and quantified luminescence from each mouse at day 57 demonstrated a decrease in tumor burden only when the a-Her2-EE zipFv that binds to zipCAR was injected ( Figures 3B  and 3C ). We also measured the cytokine release in vivo to verify that cytokine production is specific to the binding between zipFv and zipCAR. As expected, the injection of a-Her2-RR zipFv did not increase IFN-g level in vivo. However, the administration of the a-Her2-EE zipFv showed a significant increase in IFN-g after 24 hr of CD8+ T cells and zipFv injection ( Figure 3D ).
Intraperitoneal xenograft tumor models are frequently used to evaluate immunotherapy against human ovarian cancers (Geller et al., 2013; Lee et al., 2002; Lengyel et al., 2014; Shaw et al., 2004) , but demonstrating the efficacy of the SUPRA system with a blood tumor model could further validate the applicability of this system against different tumors (e.g., T cell cancers). As such, we also tested the SUPRA system against a blood tumor model. We injected modified Jurkat T cancer cells (engineered to be Her2 positive) intravenously into immunocompromised NSG mice. After 3 days, we injected primary CD8+ human T cells expressing RR zipCAR or conventional Her2 CAR into the mice. a-Her2-EE zipFv was subsequently injected every day at 3 mg/kg for 6 days. Tumor growth was monitored by IVIS of the luciferase signal from Jurkat cancer cells in each mouse over the course of 21 days. RR zipCAR with a-Her2-EE zipFv showed robust tumor burden clearance, comparable to the conventional Her2 CAR. However, T cells expressing RR zipCAR alone without zipFvs were not able to reduce tumor burden ( Figure 3E ). Moreover, long-term survival rate was observed for the group that received both RR zipCAR with a-Her2-EE zipFv ( Figure S5A ). We further characterized our SUPRA CAR system in this blood tumor model by modulating T cell numbers (from 10 3 10 6 per mice to 2.5 3 10 6 per mice) and lowering zipFv dose to 1 mg/kg ( Figures S5B and S5C ). At these reduced T cell numbers and zipFv doses, robust reduction of tumor burden was still observed. The observed robust activity of the SUPRA system against different xenograft tumor models demonstrates the potential of the SUPRA CAR system to combat many different cancers.
Characterization of the Humanized SUPRA CAR System
In Vitro and In Vivo To mitigate the potential immunogenicity against synthetic leucine zippers, we created a new zipCAR and zipFv pair using zipper domains derived from human FOS and JUN transcription factors, respectively (Karin et al., 1997; Reinke et al., 2010) . Human primary CD8+ T cells were engineered to express a FOS zipCAR. An a-Her2-JUN zipFv was used to activate the FOS zipCAR ( Figure S6A ). FOS-zipCAR-and RR-zipCAR-engineered CD8+ T cells have comparable in vivo killing efficiencies against Jurkat T cells that express Her2 ( Figure S6A ). In addition, FOS zipCAR can be activated only when a-Her2-JUN zipFv and Her2-expressing tumor cells are present, as measured by CD69 expression and IFN-g secretion ( Figures S6B and S6C ). FOS zipCAR with a-Her2-JUN zipFv can efficiently eliminate leukemia in vivo as demonstrated in a blood tumor model ( Figure S6D ). Together, these results illustrate that the SUPRA components can be humanized to reduce potential immunogenicity and that they are as effective as the ones derived from synthetic zippers.
Controlling SUPRA CAR Activity In Vivo Strategies that enable controlled cytokine production by CAR T cells in vivo are critical to preventing cytokine release the total flux (photons/s) from the luciferase activity of each mouse using IVIS imaging. (Right) Representative IVIS images of groups treated with (1) no T cells, (2) conventional Her2 CAR, (3) RR zipCAR, and (4) RR zipCAR with EE zipFv at day 21 (n = 4, mean ± SEM, statistical significance was determined by Student's t test, * = p % 0.05, *** = p % 0.001).
See also Figures S4 and S5 .
syndrome (Maude et al., 2014b; Morgan et al., 2010) . As such, we explored in vivo cytokine production by SUPRA CAR T cells in a zipFv dose-dependent manner. We first injected SK-BR-3 breast cancer cells and allowed the tumor to be established (Figure S4C ). After verifying tumor establishment, RR-zipCAR-expressing CD8+ T cells were injected and mice were dosed with 8, 4, 2, or 0.5 mg/kg of the a-Her2-EE zipFv every other day for 2 weeks ( Figure S4C ). Again, the tumor burden was monitored by IVIS of the luciferase signal from SK-BR-3 cancer cells in each mouse. Increasing zipFv dose beyond 2 mg/kg (e.g., 4 mg/kg or 8 mg/kg) resulted in faster and more efficient killing of cancer cells. There were no significant differences between groups that received 0.5 mg/kg and 2 mg/kg or between groups that received 4 mg/kg and 8 mg/kg ( Figure S4D ). However, zipFv dosage correlated with cytokine release in vivo in a stepwise fashion, which demonstrates the possibility of using the SUPRA CAR to finely regulate cytokine release in vivo ( Figure 4A ). We also examined if in vivo cytokine production could be modulated with different leucine zippers (SYN3, SYN5, EE) or a-Her scFv (G98, ML39, and H3B1) affinity on the zipFv (4 mg/kg) ( Figures 4B and S4E) . Indeed, in vivo IFN-g release correlated with the affinity between leucine zippers ( Figure 4B ). The cytokine release also increased as the scFv changed from low (G98, K d = 3.2 X 10 À7 ) to medium-high affinity (ML39, H3B1, K d < 1 X 10 À8 ). However, as shown in the in vitro results, Figure 3D ; n = 4, mean ± SD). (B) In vivo IFN-g cytokine level at 24 hr, demonstrating a leucine zipper affinity-dependent increase of in vivo IFN-g cytokine (n = 4, mean ± SD). (C) In vivo IFN-g cytokine level demonstrating the effect of competitive zipFv (the no-zipFv EE conditions are the same as groups shown in B; n = 4, mean ± SD, statistical significance was determined by Student's t test, * = p % 0.05, *** = p % 0.001). See also Figure S4 .
zipFvs with medium-high binding domain affinity (ML39, H3B1, K d < 1 X 10 À8 ) did not increase IFN-g secretion ( Figure S4E ). Lastly, we investigated if the SUPRA CAR could be inhibited in vivo with a competitive zipFv to reduce cytokine production ( Figure 4C ). As expected, the group that only received a-Her2-EE zipFv (4 mg/kg) secreted a high level of IFN-g. Moreover, when a competitive zipFv (8 mg/kg) that can bind to the activating zipFv was added (SYN4), the IFN-g level reduced significantly, similar to that of the no-zipFv control. However, addition of a control zipFv, which does not bind to the activating EE zipFv, did not decrease cytokine release in vivo (SYN13). We did not observe a significant effect of competitive zipFvs on the antitumor cytotoxicity in vivo. However, in vivo cytokine production results demonstrate that the SUPRA CAR platform affords multiple approaches to control cytokine production, providing the tools needed to manage severe cytokine release syndrome and other potential toxicities that arise from conventional CAR T cell therapies.
Controlling Different Signaling Domains Using
Orthogonal SUPRA CARs Currently, only a small number of signaling domains are being utilized in CAR T cell therapy to regulate T cell responses. Moreover, we lack independent control of different signaling domains as they are activated simultaneously. However, the repertoire of co-signaling domains-both co-stimulatory and co-inhibitory domains-are highly diverse, and it is the activation of different co-signaling domains that sculpts ultimate T cell function (Chen and Flies, 2013; Greenwald et al., 2005; Zhu et al., 2011) . One of the key attributes of the SUPRA CAR design is that multiple orthogonal SUPRA CARs can be designed to control distinct signaling pathways in the same cell, which provides highly customizable tuning of T cell signaling and response. To identify orthogonal SUPRA CARs, Jurkat T cells expressing different zipCARs were co-cultured with Her2+ K562 target cells and different zipFvs. (Figures S7A and S7B) . From the screen, we identified several pairs of orthogonal SUPRA CARs ( Figure S7C ). We then engineered two orthogonal SUPRA CARs to regulate separate signaling pathways in primary CD4+ T cells: FOS zipCAR (binds to a-Her2-SYN9 zipFv) that contains only a CD3z domain and RR zipCAR (binds to a-Axl-EE zipFv) that contains CD28 and 4-1BB co-stimulatory domains ( Figure 5A ). We chose these signaling domains because they have been used previously for demonstrating combinatorial antigen detection in vivo (Kloss et al., 2013) . To trigger each zipCAR independently, we co-cultured engineered CD4+ T cells and K562 target cells that express Her2 and Axl. We then added two different zipFvs at varying concentrations and measured CD69 expression, which can be triggered by CD28 activation (Vandenberghe et al., 1993) . Triggering CD3z alone increased CD69 expression. Activating the CD28/4-1BB and CD3z domains, however, led to a further increase in CD69 expression (Figures 5B and S7F ). To confirm this dual antigen-sensing functionality, we also measured different cytokine (IFN-g, IL-2, and IL-4) levels that are known to be regulated by CD28 and 4-1BB signaling (Howland et al., 2000; Kane et al., 2001; Lucas et al., 1995) . For all cytokines tested, we observed similar synergistic antigen detection logic effects of these two receptors ( Figures 5B and  S7D-S7F) . Surprisingly, the effect of the CD28 and 4-1BB co-stimulatory signaling was much higher when we increased the a-Her2-SYN9 zipFv concentration (as CD3z signaling strength increased) ( Figure S7F ).
Controlling Different Cell Types Using Orthogonal SUPRA CARs
We recognized that orthogonal SUPRA CARs can also be used to control different T cell subtypes, such as CD4+ and CD8+ T cells ( Figure 6A ). CD4+ T cells are helper T cells that secrete a variety of cytokines and regulate the immune responses such as activation, growth, and memory formation of CD8+ T cells (Luckheeram et al., 2012) . CD8+ T cells are cytotoxic T cells that can directly kill cancer cells. As the use of both CD4+ and CD8+ T cells has been shown to enhance the antitumor response of CAR T cells (Turtle et al., 2016) , independent control of both cell types to induce different T cell reponses could further improve the effectiveness of CAR T cell therapy. To demonstrate orthogonal control of both T cell types, we introduced an RR zipCAR into CD4+ T cells (binds to a-Axl-EE zipFv) and an orthogonal FOS zipCAR (binds to the a-Her2-SYN9 zipFv) into CD8+ T cells. All zipCARs here contain CD3z, CD28, and 4-1BB signaling domains. To trigger each cell type independently, we co-cultured both engineered CD4+ and CD8+ T cells with K562 cells that express Axl and Her2 ( Figure 6A ). CD69 expression level was upregulated in CD4+ or CD8+ T cells only in response to the addition of a-Axl zipFv or a-Her2 zipFv, respectively. When both zipFvs were added simultaneously, the CD69 level was upregulated for both cell types (Figure 6B) . Furthermore, activating both cell types simultaneously achieved IFN-g secretion levels similar to the sum of cytokine secretion levels from two subsets of T cells activated individually ( Figure 6C ). Finally, 24-hr co-culture of CD4+ and CD8+ T cells with Axl+/Her2+ K562 cells led to cytotoxicity against tumor cells (as measured by K562 population percentage through flow cytometry) when CD8+ T cells were activated, but minimally for CD4+ T cells (Hombach et al., 2006) (Figure 6D ).
DISCUSSION
SUPRA CAR: The Swiss Army Knife of CAR There is a great need for a flexible platform that can control T cell activation with improved precision and tunability to make CAR T cell therapy safer and more effective. Here, we have developed a split CAR system with enhanced flexibility, specificity, and controllability. We demonstrated that our SUPRA CAR system can target different antigens without having to re-engineer the (A) Design of orthogonal SUPRA CARs that control either CD3z or CD28/4-1BB signaling domains. The RR zipCAR and FOS zipCAR contain CD28/4-1BB co-stimulatory and CD3z signaling domains, respectively. a-Her2 zipFv binds to the FOS zipCAR and activates the CD3z domain, whereas the a-Axl zipFv binds to the RR zipCAR and activates CD28/4-1BB co-stimulatory domains. CD69 expression and IFN-g, IL-2, and IL-4 secretion were measured as outputs. (B) Amount of each zipFv was varied to define signaling strength from each receptor. CD69 expression (left) and IFN-g secretion (right) were measured (n = 3, mean). See also Figure S7 .
T cells. The activity of the SUPRA CAR system can also be flexibly modulated through multiple mechanisms. In addition, the SUPRA CAR can be easily designed for combinatorial logic antigen detection and regulate different signaling pathways in the same cell, as well as different cell types independently. Together, the SUPRA CAR represents a feature-rich receptor system for adoptive T cell therapy.
While several split systems have been introduced with biomolecule-labeled antibodies (Kudo et al., 2014; Ma et al., 2016; Rodgers et al., 2016; Tamada et al., 2012; Urbanska et al., 2012) to redirect the specificity of CARs, none of these systems have demonstrated the same level of flexibility and functionality as our SUPRA CAR system. Furthermore, some of the systems require extensive and non-intuitive optimization of the receptor design. The modular design approach of our SUPRA CAR platform, however, allows convenient redirection of target specificity and adjustment to T cell activity. Several structural parameters, such as the location of the scFv binding to the antigen, scFv affinity, and extracellular spacing (Hudecek et al., 2015; Rodgers et al., 2016; Zah et al., 2016) , are important to the CAR signaling. Given that the leucine zipper design constrains some of the structure parameters (e.g., the extracellular spacing) of the zipCAR, further investigation would be needed to determine the effect of these parameters on the SUPRA CAR system activity.
We were able to generate zipFvs targeting three different targets without having to individually optimize each zipFv. Moreover, we showed that SUPRA CAR components can be humanized by using leucine zipper domains derived from human transcription factors to reduce potential immunogenicity. Because these endogenous leucine zippers are localized inside the cells, we do not expect crosstalk to occur between humanized SUPRA CAR components and human transcription factors. In addition, although not investigated here, we anticipate that each zipFv will have a short pharmacokinetic half-life in vivo, similar to an scFv (Gould et al., 2005) , which could allow increased temporal control, and we expect that its small size will lead to increased tumor penetration (Carter, 2001 ). However, the short serum half-life could also be problematic, as the SUPRA system requires zipFvs to maintain in vivo T cell activity. Nonetheless, SUPRA CAR T cells were able to clear tumor burden in vivo with a zipFv dose comparable to other FDA-approved protein drugs. Moreover, several well-developed protein engineering approaches are available (e.g., PEGylation, Fc/Albumin fusion, glycoengineering) to increase half-life of scFv, which can be employed to modulate zipFv stability in vivo if necessary (Kimchi-Sarfaty et al., 2013; Kontermann, 2011; Strohl, 2015; Szlachcic et al., 2011) .
SUPRA CAR Could Enhance the Safety of T Cell Therapy
Controlling cytokine secretion is critical to limiting cytokine release syndrome in patients. We were able to titrate cytokine secretion and cytotoxicity with different zipFv doses and configurations, demonstrating the tunabilty of the SUPRA system in vivo. Furthermore, we showed through the use of competitive leucine zippers for OFF-switch function that one can significantly reduce cytokine secretion both in vitro and in vivo. Moreover, this competition-based strategy can improve target specificity by directing the competitive zipFv toward a surface marker for ''normal'' cells, thus safeguarding them from being targeted by the zipCAR. We anticipate that to efficiently block the accessibility of zipCAR, the expression level of the cancer cell marker and the normal cell marker will need to be comparable.
Toward the Synthesis of a Prosthetic Immune System
A central feature of the SUPRA CAR system is the availability of orthogonal zippers with varying affinity (Reinke et al., 2010) , providing a valuable resource for engineering facile and complex control of T cell signaling. Most CARs have been designed as a single receptor controlling all the necessary signaling domains at the same time at a preset (but undefined) level. In contrast, we have shown that multiple orthogonal SUPRA CARs can be utilized to control different signaling domains (e.g., CD3z, CD28, 4-1BB), which enable independent and tunable control of different signaling pathways. Moreover, each CAR can be paired with zipFvs that target different tumor antigens or with a different affinity of the leucine zipper, thus allowing regulatable combinatorial antigen sensing, a useful feature that has not been achieved in other CAR or receptor systems ( Figure 7A ). Furthermore, previous designs for combinatorial antigen sensing using two CARs often require precise control of the expression level of each receptor or careful choice of scFv affinity to achieve an optimal balance of signaling strength (Kloss et al., 2013) . While useful and novel, such designs lack the flexibility to combat tumor relapse due to antigen escape, which will require extensive design of a different dual CAR system. However, with the SUPRA system, the zipFv composition can be simply changed, and the signaling strength from each receptor can be easily tuned by the amount Figure 7 . Engineering a Prosthetic Immune System with SUPRA CARs (A) The SUPRA CAR system enables the flexible and advanced control of signaling in T cells, reminiscent of an audio-mixing console for controlling audio signals. The affinity and dosage of each zipFv are like knobs and dials on the mixing console, which can be varied to achieve userdefined T cell activation levels. Different orthogonal pairs of SUPRA CARs are like different channels, which can be utilized to control different signaling pathways in the same cells. (B) The SUPRA CAR system can also be implemented in other cell types, thus setting the foundation for creating a prosthetic immune system. of zipFv, rather than re-engineering T cells, to meet the challenge of antigen escape.
In addition to regulating different signaling pathways, multiple orthogonal SUPRA CARs can also be used to control different subsets of immune cells. Current CAR-based therapy is typically implemented in a cell mixture (e.g., peripheral blood mononuclear cells) or single subsets of immune cell types (e.g., CD4+, CD8+, Treg, or NK cells; Glienke et al., 2015; Klingemann, 2014; MacDonald et al., 2016; Yoon et al., 2017) . Even when two defined T cell subsets (CD4+ and CD8+) were utilized, they were not regulated independently. Given that our immune system is composed of many different cell types with unique effector functions and behaviors in vivo, a platform that enables independent control of different cell types could greatly increase the range of responses that can be achieved by the engineered cells ( Figure 7B ). As a proof of concept, we engineered two different T cells subtypes (CD4+ and CD8+) and demonstrated that two orthogonal SUPRA receptors can independently regulate two cell types. While it is possible to engineer two cell types with conventional fixed CARs that target different antigens, our SUPRA system enables the first orthogonal inducible control of two cell types simultaneously. We anticipate that the SUPRA system can also be applied to regulatory T cells and NK cells, along with CD4+ and CD8+ T cells, to form a prosthetic immune system that allows unparalleled control for cell-based immunotherapy ( Figure 7B ).
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHAING
Further information and requests for reagents and resources should be directed and will be fulfilled by Lead Contact, Wilson W. Wong (wilwong@bu.edu).
EXPERIEMENTAL MODEL AND SUBJECT DETAILS
Source of Primary Human T Cells Anonymous healthy donor blood was obtained from the Blood Donor Center at Boston Children's Hospital (Boston, MA) as approved by the University Institutional Review Board. Primary CD4+ and CD8+ T cells were isolated from anonymous donor blood by negative selection (described in METHOD DETAILS).
Animal Model Details
All experimental procedures were conducted at the Boston University Medical School Animal Science Center (BUASC) under a protocol approved by the Boston University Institutional Animal Care and Use Committee. Female immunocompromised NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice, 4-6 week of age, were purchased from Jackson Laboratories (#005557). Mice used in the experiment were healthy and immunocompromised. These animals were not involved in previous procedures and drug or test naive. These mice were housed in sterile cages at BUASC with 12hr light/dark cycle. Health and immune status of mice were monitor daily by BUASC husbandry staff. Mice were euthanized during experiment if they showed hunched abnormal posture, impaired mobility, rough coat, or paralysis.
METHOD DETAILS
zipCAR Receptor Construct Design zipCARs were designed by fusing different leucine zippers (Reinke et al., 2010; Thompson et al., 2012) to the hinge region of the human CD8a chain and transmembrane and cytoplasmic regions of the human CD28, 4-1BB, and CD3z signaling endodomains. They were under SFFV promoter for all primary T cell experiments and under CAG promoter for all Jurkat cell experiments. All zipCARs contain myc tag to verify surface expression. Furthermore, zipCARs used in primary T cell experiments were fused to mCherry after CD3z chain to visualize expression. zipCARs used in Jurkat experiments were cloned into the piggyback vector (System Bioscience), which has been modified by replacing CMV promoter to CAG promoter. zipFv Construct Design The general design of zipFv is as follows. scFv (a-HER2, a-Axl or a-MESO) is linked by a 35-aa glycine/serine linker to leucine zipper. Constructs were cloned into pSecTag2A vectors (Thermo Fisher) for transient expression. These vectors contain the CMV promoter, murine Ig-k-chain leader sequence, C-terminal c-myc epitope, and a 6X His tag for purification.
